 Suchitra Rao
Concepts (273)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 40 | 2026 | 624 | 11.190 |
Why?
| | Influenza Vaccines | 21 | 2026 | 534 | 5.390 |
Why?
| | Vaccination | 23 | 2026 | 1426 | 3.230 |
Why?
| | Respiratory Syncytial Virus Infections | 5 | 2025 | 139 | 2.410 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 396 | 2.310 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2024 | 81 | 2.170 |
Why?
| | Hospitalization | 34 | 2026 | 2460 | 2.120 |
Why?
| | Systemic Inflammatory Response Syndrome | 6 | 2024 | 95 | 1.710 |
Why?
| | Child | 67 | 2026 | 22707 | 1.590 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2025 | 159 | 1.530 |
Why?
| | Child, Preschool | 48 | 2026 | 11853 | 1.510 |
Why?
| | Emergency Service, Hospital | 19 | 2025 | 2381 | 1.440 |
Why?
| | Infant | 35 | 2026 | 10077 | 1.400 |
Why?
| | Antiviral Agents | 9 | 2026 | 769 | 1.270 |
Why?
| | Influenza A Virus, H3N2 Subtype | 7 | 2026 | 50 | 1.210 |
Why?
| | Retrospective Studies | 34 | 2026 | 17291 | 1.050 |
Why?
| | Immunization Programs | 2 | 2026 | 193 | 0.980 |
Why?
| | Absenteeism | 2 | 2024 | 52 | 0.970 |
Why?
| | Humans | 114 | 2026 | 145474 | 0.960 |
Why?
| | Coinfection | 2 | 2022 | 143 | 0.950 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 85 | 0.930 |
Why?
| | Oseltamivir | 3 | 2025 | 17 | 0.910 |
Why?
| | Ambulatory Care | 10 | 2026 | 609 | 0.900 |
Why?
| | Pandemics | 5 | 2026 | 1707 | 0.900 |
Why?
| | Polyomavirus Infections | 3 | 2016 | 30 | 0.890 |
Why?
| | Adolescent | 52 | 2026 | 22529 | 0.870 |
Why?
| | Croup | 1 | 2024 | 19 | 0.850 |
Why?
| | Polyomavirus | 3 | 2016 | 11 | 0.850 |
Why?
| | Immunocompromised Host | 3 | 2021 | 202 | 0.840 |
Why?
| | Bronchiolitis | 1 | 2024 | 87 | 0.790 |
Why?
| | Colorado | 12 | 2023 | 4553 | 0.780 |
Why?
| | Autoimmune Diseases | 2 | 2026 | 468 | 0.780 |
Why?
| | Ageusia | 1 | 2022 | 1 | 0.760 |
Why?
| | Metapneumovirus | 1 | 2022 | 15 | 0.740 |
Why?
| | Male | 61 | 2026 | 72842 | 0.740 |
Why?
| | Seizures | 3 | 2024 | 483 | 0.700 |
Why?
| | Female | 61 | 2026 | 78844 | 0.690 |
Why?
| | Myocarditis | 1 | 2022 | 102 | 0.680 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2021 | 288 | 0.670 |
Why?
| | Seasons | 10 | 2025 | 538 | 0.640 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 103 | 0.640 |
Why?
| | Viruses | 1 | 2022 | 165 | 0.620 |
Why?
| | Endpoint Determination | 1 | 2020 | 85 | 0.620 |
Why?
| | Family Characteristics | 6 | 2026 | 195 | 0.600 |
Why?
| | Respiratory Tract Diseases | 2 | 2021 | 175 | 0.580 |
Why?
| | Birth Order | 1 | 2019 | 14 | 0.580 |
Why?
| | United States | 37 | 2026 | 16098 | 0.580 |
Why?
| | Advisory Committees | 1 | 2020 | 229 | 0.570 |
Why?
| | Onchocerciasis | 2 | 2015 | 8 | 0.560 |
Why?
| | Streptococcal Infections | 1 | 2021 | 171 | 0.550 |
Why?
| | Sinusitis | 1 | 2021 | 227 | 0.550 |
Why?
| | Encephalitis | 2 | 2017 | 142 | 0.550 |
Why?
| | Electronic Health Records | 7 | 2026 | 1196 | 0.510 |
Why?
| | Cohort Studies | 14 | 2026 | 6013 | 0.500 |
Why?
| | Nervous System Diseases | 1 | 2020 | 286 | 0.500 |
Why?
| | Viral Load | 4 | 2024 | 526 | 0.490 |
Why?
| | Medical Audit | 1 | 2016 | 77 | 0.480 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 361 | 0.470 |
Why?
| | Leukoencephalitis, Acute Hemorrhagic | 2 | 2025 | 5 | 0.460 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1923 | 0.450 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 87 | 0.440 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 42 | 0.440 |
Why?
| | Virus Shedding | 2 | 2026 | 49 | 0.430 |
Why?
| | Young Adult | 22 | 2026 | 14218 | 0.420 |
Why?
| | Acyclovir | 1 | 2015 | 98 | 0.420 |
Why?
| | Attitude to Health | 1 | 2017 | 430 | 0.420 |
Why?
| | Case-Control Studies | 9 | 2023 | 3623 | 0.410 |
Why?
| | Enterovirus Infections | 1 | 2016 | 173 | 0.410 |
Why?
| | Ritonavir | 2 | 2024 | 75 | 0.400 |
Why?
| | Hospitals, Pediatric | 2 | 2025 | 558 | 0.400 |
Why?
| | Infant, Newborn | 11 | 2025 | 6447 | 0.390 |
Why?
| | Adult | 38 | 2026 | 40777 | 0.380 |
Why?
| | Health Promotion | 1 | 2019 | 775 | 0.380 |
Why?
| | Infection Control | 1 | 2014 | 173 | 0.370 |
Why?
| | Mothers | 1 | 2019 | 765 | 0.370 |
Why?
| | Body Mass Index | 4 | 2026 | 2445 | 0.360 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1767 | 0.360 |
Why?
| | Virus Diseases | 1 | 2014 | 216 | 0.350 |
Why?
| | Inpatients | 3 | 2026 | 553 | 0.350 |
Why?
| | Outpatients | 3 | 2025 | 447 | 0.350 |
Why?
| | Brain Diseases | 2 | 2025 | 155 | 0.350 |
Why?
| | Cross Infection | 1 | 2014 | 260 | 0.340 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1371 | 0.340 |
Why?
| | Anticonvulsants | 2 | 2024 | 246 | 0.330 |
Why?
| | Hematologic Diseases | 1 | 2011 | 66 | 0.330 |
Why?
| | Health Personnel | 1 | 2017 | 754 | 0.330 |
Why?
| | Cost of Illness | 3 | 2026 | 324 | 0.320 |
Why?
| | Immunization, Secondary | 4 | 2022 | 92 | 0.310 |
Why?
| | Liver Abscess, Amebic | 1 | 2009 | 3 | 0.290 |
Why?
| | Stomach Rupture | 1 | 2009 | 3 | 0.290 |
Why?
| | Pericardial Effusion | 1 | 2009 | 22 | 0.290 |
Why?
| | Parents | 1 | 2017 | 1403 | 0.280 |
Why?
| | Program Evaluation | 2 | 2025 | 943 | 0.280 |
Why?
| | Prospective Studies | 8 | 2026 | 8057 | 0.280 |
Why?
| | Risk Factors | 10 | 2025 | 10885 | 0.280 |
Why?
| | Peritonitis | 1 | 2009 | 83 | 0.280 |
Why?
| | Pleural Effusion | 1 | 2009 | 59 | 0.270 |
Why?
| | Influenza A virus | 2 | 2026 | 119 | 0.270 |
Why?
| | Electroencephalography | 2 | 2024 | 561 | 0.260 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 875 | 0.250 |
Why?
| | Severity of Illness Index | 5 | 2025 | 2930 | 0.250 |
Why?
| | Motivation | 2 | 2022 | 600 | 0.240 |
Why?
| | Angiostrongylus cantonensis | 2 | 2018 | 3 | 0.240 |
Why?
| | Strongylida Infections | 2 | 2018 | 8 | 0.240 |
Why?
| | Aged | 19 | 2026 | 26153 | 0.230 |
Why?
| | Middle Aged | 23 | 2026 | 36215 | 0.230 |
Why?
| | Steroids | 1 | 2026 | 160 | 0.230 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 137 | 0.220 |
Why?
| | Population Surveillance | 2 | 2025 | 484 | 0.210 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 39 | 0.210 |
Why?
| | Dyslipidemias | 1 | 2026 | 184 | 0.200 |
Why?
| | Disease Progression | 4 | 2024 | 2864 | 0.200 |
Why?
| | Pediatrics | 2 | 2025 | 1121 | 0.200 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 133 | 0.200 |
Why?
| | Antigens, Viral | 1 | 2024 | 182 | 0.190 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 337 | 0.190 |
Why?
| | Vaccines, Combined | 4 | 2023 | 49 | 0.190 |
Why?
| | RNA, Messenger | 7 | 2024 | 2803 | 0.190 |
Why?
| | Physicians | 2 | 2023 | 955 | 0.190 |
Why?
| | Child, Hospitalized | 1 | 2023 | 54 | 0.190 |
Why?
| | Dermatitis, Atopic | 1 | 2026 | 322 | 0.190 |
Why?
| | Vital Signs | 1 | 2022 | 46 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2023 | 107 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 377 | 0.180 |
Why?
| | Length of Stay | 2 | 2025 | 1349 | 0.180 |
Why?
| | Cough | 1 | 2022 | 124 | 0.170 |
Why?
| | Incidence | 3 | 2026 | 2923 | 0.170 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.170 |
Why?
| | Patient Readmission | 2 | 2024 | 769 | 0.170 |
Why?
| | Guideline Adherence | 1 | 2025 | 586 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 881 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2026 | 8333 | 0.160 |
Why?
| | Drug Utilization | 2 | 2024 | 168 | 0.160 |
Why?
| | Public Health | 1 | 2025 | 572 | 0.160 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.150 |
Why?
| | Algorithms | 2 | 2025 | 1845 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 992 | 0.150 |
Why?
| | Encephalitis, Viral | 1 | 2020 | 45 | 0.150 |
Why?
| | Immunization Schedule | 2 | 2021 | 186 | 0.150 |
Why?
| | Bayes Theorem | 3 | 2026 | 420 | 0.150 |
Why?
| | Critical Pathways | 1 | 2020 | 109 | 0.150 |
Why?
| | Antibodies, Viral | 2 | 2023 | 674 | 0.140 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 133 | 0.140 |
Why?
| | Reminder Systems | 1 | 2019 | 140 | 0.140 |
Why?
| | Information Dissemination | 1 | 2020 | 224 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 275 | 0.130 |
Why?
| | Infant, Small for Gestational Age | 1 | 2019 | 118 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 156 | 0.130 |
Why?
| | Oxygen | 1 | 2023 | 978 | 0.130 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 232 | 0.130 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 440 | 0.130 |
Why?
| | Needs Assessment | 1 | 2020 | 402 | 0.130 |
Why?
| | Time Factors | 5 | 2026 | 7123 | 0.130 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 243 | 0.130 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 74 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2020 | 166 | 0.130 |
Why?
| | Nurses | 1 | 2019 | 171 | 0.130 |
Why?
| | Pneumonia | 2 | 2016 | 636 | 0.130 |
Why?
| | Disease Outbreaks | 2 | 2020 | 419 | 0.130 |
Why?
| | Adiposity | 1 | 2022 | 532 | 0.130 |
Why?
| | Philippines | 1 | 2016 | 51 | 0.120 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 68 | 0.120 |
Why?
| | Onchocerca | 1 | 2015 | 2 | 0.120 |
Why?
| | Fatigue | 1 | 2018 | 364 | 0.120 |
Why?
| | Nasal Cavity | 1 | 2016 | 61 | 0.120 |
Why?
| | Urban Population | 1 | 2019 | 493 | 0.110 |
Why?
| | Influenza B virus | 2 | 2025 | 47 | 0.110 |
Why?
| | Patient Discharge | 2 | 2019 | 992 | 0.110 |
Why?
| | Neoplasms | 1 | 2011 | 2906 | 0.110 |
Why?
| | Zoonoses | 1 | 2015 | 38 | 0.110 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 39 | 0.110 |
Why?
| | Catheterization, Peripheral | 1 | 2016 | 120 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 21 | 0.110 |
Why?
| | Critical Care | 1 | 2021 | 702 | 0.110 |
Why?
| | Hospital Mortality | 3 | 2025 | 1038 | 0.110 |
Why?
| | Dog Diseases | 1 | 2015 | 86 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1163 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 669 | 0.100 |
Why?
| | Asthma | 1 | 2026 | 1797 | 0.100 |
Why?
| | Hospitals | 3 | 2024 | 732 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 428 | 0.100 |
Why?
| | Rural Population | 1 | 2019 | 659 | 0.100 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 168 | 0.100 |
Why?
| | Vaccination Coverage | 2 | 2025 | 102 | 0.100 |
Why?
| | Pregnancy | 3 | 2022 | 7202 | 0.090 |
Why?
| | Transcriptome | 1 | 2019 | 1038 | 0.090 |
Why?
| | Survival Rate | 1 | 2017 | 2090 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 80 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1295 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2134 | 0.080 |
Why?
| | Decision Making | 1 | 2018 | 977 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 110 | 0.080 |
Why?
| | Eosinophilia | 1 | 2013 | 223 | 0.080 |
Why?
| | Critical Illness | 1 | 2016 | 900 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6066 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2406 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1747 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 3 | 0.070 |
Why?
| | Administration, Oral | 2 | 2026 | 866 | 0.070 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.070 |
Why?
| | DNA, Viral | 1 | 2011 | 356 | 0.070 |
Why?
| | Entamoeba histolytica | 1 | 2009 | 9 | 0.070 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 15 | 0.070 |
Why?
| | Metronidazole | 1 | 2009 | 20 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5904 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1267 | 0.070 |
Why?
| | Drainage | 1 | 2009 | 185 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2865 | 0.070 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.060 |
Why?
| | Insect Bites and Stings | 1 | 2007 | 13 | 0.060 |
Why?
| | Culicidae | 1 | 2007 | 33 | 0.060 |
Why?
| | Intensive Care Units | 2 | 2025 | 924 | 0.060 |
Why?
| | Plasmodium falciparum | 1 | 2007 | 37 | 0.060 |
Why?
| | Malaria, Falciparum | 1 | 2007 | 32 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2023 | 11772 | 0.060 |
Why?
| | Viral Proteins | 1 | 2009 | 350 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3922 | 0.060 |
Why?
| | Animals | 6 | 2018 | 38030 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2953 | 0.060 |
Why?
| | Plasmapheresis | 1 | 2025 | 24 | 0.060 |
Why?
| | Contact Tracing | 1 | 2025 | 26 | 0.060 |
Why?
| | Basic Reproduction Number | 1 | 2025 | 6 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 699 | 0.050 |
Why?
| | Safety | 1 | 2007 | 358 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1508 | 0.050 |
Why?
| | Lopinavir | 1 | 2024 | 30 | 0.050 |
Why?
| | Brain | 1 | 2017 | 2947 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2025 | 251 | 0.050 |
Why?
| | Immunity, Herd | 1 | 2024 | 7 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 147 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3904 | 0.050 |
Why?
| | Pediatricians | 1 | 2025 | 121 | 0.050 |
Why?
| | Genotype | 1 | 2009 | 1852 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2025 | 310 | 0.050 |
Why?
| | Spermine | 1 | 2023 | 29 | 0.050 |
Why?
| | Acute Disease | 1 | 2026 | 1036 | 0.050 |
Why?
| | Acetamides | 1 | 2023 | 41 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 396 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Bradycardia | 1 | 2023 | 61 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2024 | 168 | 0.050 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 120 | 0.040 |
Why?
| | Patient Acuity | 1 | 2022 | 48 | 0.040 |
Why?
| | Diabetic Ketoacidosis | 1 | 2023 | 209 | 0.040 |
Why?
| | Obesity | 2 | 2024 | 3116 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1997 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2023 | 479 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2769 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1137 | 0.030 |
Why?
| | Machine Learning | 1 | 2023 | 587 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1581 | 0.030 |
Why?
| | Pediatric Obesity | 1 | 2024 | 638 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1323 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 172 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1661 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5423 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1490 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 93 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 360 | 0.030 |
Why?
| | Cats | 1 | 2015 | 231 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3155 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3747 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 458 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3342 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2013 | 26 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1041 | 0.020 |
Why?
| | Cross Reactions | 1 | 2009 | 130 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 171 | 0.020 |
Why?
| | Age Distribution | 1 | 2009 | 403 | 0.020 |
Why?
| | Parasitemia | 1 | 2007 | 15 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 848 | 0.020 |
Why?
|
|
Rao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|